show episodes
 
Decision making, problem-solving and leadership buy-in are some of the biggest challenges executives face in the rapid pace of business today. Modelled after the well-known idea of café conversations, Generis' Executive Corner is a collection of purposeful conversations where we discuss real issues with industry trailblazers and offer valuable and actionable insights that you can start implementing today! Executive Corner is a must-listen podcast and the premier hub for active learners, deci ...
 
Whitehat is an Inbound Marketing Agency based in London. We work with B2B companies within the pharmaceutical & life science, technology (hardware & software), manufacturing, charity and educational sectors. These companies tend to be located within the UK or continental Europe and have an average turnover of between £5M and £100M. Their sales cycle is often 6 months or more. They typically have an active direct sales team of at least 5 people but with little or no internal marketing capability.
 
Diamond Systems LLC is a Veteran Administration verified VOSB and HUBZONE Certified Company providing field and fixed laboratory and portable products, safety equipment, for clinical, research, environmental, and hazardous applications. Our customers and focus includes IVF labs, food, brewery, pharmaceutical sciences, air and water quality researchers, landfill-bio digester applications and safety equipment for toxic gas, national security and personal protection. Over 30 years of experience ...
 
On paper, we are a technology-driven biopharmaceutical solutions company. But on a daily basis, we make sure patients come first. We do this by providing biopharmaceutical manufacturers with an integrated suite of solutions that enhance patient and provider experiences. And better experiences lead to better outcomes. When TrialCard was founded in 2000, we knew that an all-inclusive enterprise management system was essential for an easily accessible, user-friendly patient experience. We’ve sp ...
 
JAMA Health Forum is a peer-reviewed, open-access JAMA Network journal focused on health policy. The journal publishes original research, evidence-based reports, and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity, and reform. The podcast highlights new articles and their authors as well as the latest news in health policy for a broad audience interested in improving health and health c ...
 
Each episode of the Specialty Pharmacy Podcast is meant to serve as a resource for the latest specialty pharmacy trends, tips, and strategies to help listeners grow their specialty pharmacy business - be it in pharma, health systems, independents or anything in between. Tune in for valuable content, insights and actionable strategies from our rotating panel of industry experts as they share real-world examples and wisdom you can’t hear anywhere else.
 
B
Biopharma EHS

1
Biopharma EHS

Affygility Solutions, LLC

Unsubscribe
Unsubscribe
Monthly
 
BioPharma EH&S Podcast. The latest discussion on potent compound safety, occupational toxicology, industrial hygiene, and compliance management software. To submit questions or comments to the podcast email affygility@gmail.com or call our listener voicemail line at 206-984-3214.
 
Loading …
show series
 
There are many actors in the drug supply and distribution system, and little is known about the share of drug expenditures going to each, making it more difficult to rein in costs. JAMA Health Forum Associate Editor, Julie Donohue, PhD, and Deputy Editor, Melinda Buntin, PhD, speak with Neeraj Sood, PhD, lead author in a JAMA Health Forum study tha…
 
In this episode, Ayesha discussed the first FDA-approved virtual reality treatment for chronic lower back pain. The virtual reality system is called EaseVRx and is developed by virtual reality medtech company AppliedVR. The non-invasive treatment system is self-administered and is designed for at-home use. It consists of a virtual reality headset, …
 
In the latest episode of TrialCard TALK, Molly Stallings, Vice President of Product Marketing at TrialCard, discusses the evolving digital landscape and how it impacts the delivery of patient support programs. Download the podcast to hear how TrialCard is effectively engaging patients and caretakers with its life sciences multi-channel communicatio…
 
In this episode, the editorial team had the opportunity to speak with Dr. Brett Wingeier, CEO of neuromodulation MedTech company Magnus Medical about the company’s Magnus System for the treatment of major depressive disorder (MDD). The neurostimulation device received breakthrough device designation from the US Food and Drug Administration (FDA) la…
 
In this episode, the editorial team discussed Pfizer’s new oral antiviral pill for the treatment of COVID-19. Pfizer released data from an interim analysis of a Phase III trial evaluating the drug, which shows that it can reduce the risk of hospitalizations by almost 90 percent. It also prevented COVID-19 related deaths in the study. The results we…
 
In this episode, Ayesha discusses the FDA’s authorization of Pfizer/BioNTech’s COVID-19 vaccine for children between five and 11 years of age. The authorization was based on trial data that showed the vaccine was safe, well-tolerated and induced robust immune responses among children in this age group; side effects were generally mild to moderate. …
 
In this month's episode of TrialCard TALK, TrialCard's Kelly Bennett, Vice President and Practice Lead, Patient Affordability, joins us to discuss the evolution of the co-pay and financial assistance landscape. Kelly shares the many financial barriers patients encounter, and how the team has customized and enhanced the ways in which it delivers fin…
 
In this episode, the editorial team discusses the FDA approval of Cyltezo as the first interchangeable biosimilar for AbbVie’s Humira. The approval lends to the growing Humira biosimilars market, which will take off in 2023 with Boehringer Ingelheim’s Cyltezo and biosimilars from Amgen, Merck and Alvotech. AbbVie has been facing a lot of heat over …
 
In this episode, the editorial team talks about Moderna’s unwillingness to share its COVID-19 vaccine formula with other countries, namely low- and middle-income countries who continue to face issues accessing COVID-19 vaccines. The company said it would be more efficient for it to aim to produce more of the vaccines themselves to deliver to poorer…
 
In this episode, Ayesha talks about World Arthritis Day, which is on October 12 every year, with this year’s theme being raising awareness about early diagnosis. In addition to timely diagnosis, there may soon be a preventative vaccine for inflammatory arthritic conditions such as rheumatoid arthritis. Researchers at the University of Toledo have d…
 
State Medicaid programs are required to cover all drugs approved by the US Food & Drug Administration (FDA), including those that have received accelerated approval from the FDA to treat serious or life-threatening illnesses such as HIV or cancer. These drugs with accelerated approval may be beneficial based on surrogate end points such as changes …
 
In this episode, Ayesha talks about the CDC’s updated guidance according to which the COVID-19 vaccines can be administered at the same time as the flu shot and other vaccines. The new guidelines comes after the federal health agency says there is now substantial data around the COVID-19 vaccines to show that it is safe to be administered alongside…
 
In this episode, Ayesha talks about the FDA’s new interactive quiz as part of its Bad Ad outreach program that targets misleading pharmaceutical promotions. Although the Bad Ad program is primarily directed towards healthcare providers, the general public can also anonymously report dubious ads to the FDA’s Office of Prescription Drug Promotion (OP…
 
In this episode of TrialCard TALK, Landy and Eric welcomed to the studio the Engage HCP team: General Manager Mark Droke, SVP, Commercial Solutions Tom Heck, VP, Commercial Solutions Mike Davis, and Product Director Ann Poorboy. The number of no see or difficult to see HCPs has risen dramatically in recent years and has been greatly exacerbated by …
 
In this episode, Ayesha discusses the FDA’s pending decision on authorizing COVID-19 vaccine boosters for the general public. While an FDA vaccine advisory committee voted against boosters for individuals 16 years of age and older last week, the FDA is still working towards its final decision on the matter. At the same time, the advisory panel reco…
 
With RNA being the popular new “it” molecule in genetic research, Ayesha discusses Eli Lilly’s new partnership with biotech company ProQR to develop RNA-based therapeutics in this episode. The $1.5 billion deal will see Lilly leverage ProQR’s proprietary RNA editing platform to develop targets of interest. The team discusses how the success of the …
 
Knee replacements may soon be getting smarter with the world’s first smart knee implant. In this episode, Ayesha discusses a new personalized knee implant with integrated smart technology that recently received FDA clearance. Using sensors and cloud connectivity, it can help patients and practitioners monitor post-operative progress in real-time. T…
 
We know that the pandemic caused millions of people to lose their jobs, and potentially their job-based insurance, and yet new survey data showed surprisingly small changes in uninsurance rates at the end of 2020. Kate Bundorf, PhD, from the Sanford School of Public Policy at Duke University and Jessica Banthin, PhD, of the Urban Institute talk to …
 
If 20 percent of the 250 million antibiotic prescriptions written globally each year are unnecessary, are there more drug-resistant superbugs in our future? In this episode, Sarah talks about the importance of paying attention to antimicrobial resistance (AMR) and how surveillance programs will be key to preventing the next pandemic. The team debat…
 
The risk environment facing co-pay assistance programs has expanded significantly in recent years. Legislative and policy developments, payer tactics, and ill-intentioned actors present financial, operational, and compliance issues if not properly understood and addressed. TrialCard’s TC Synapse suite combines industry-leading subject matter expert…
 
In this episode, Sarah presents three ways that Alzheimer’s trials will change now that Biogen’s Aduhelm (aducanumab) has been approved by the FDA. The team discusses whether placebo-controlled trials are still ethical and how ongoing dementia studies can manage patient attrition. Can trials pivot to allow patients to aducanumab as a background the…
 
In this episode, Ayesha discussed the US Food and Drug Administration’s (FDA) authorization of a third dose of the Pfizer and Moderna COVID-19 vaccines for immunocompromised individuals. These individuals would primarily include organ transplant recipients, as well as patients taking immunosuppressive drugs for conditions like cancer and HIV/AIDS. …
 
In this episode, Ayesha discussed a presentation at this year’s Alzheimer’s Association International Conference (AAIC) 2021 about the impacts of COVID-19 on cognitive health. The study, conducted at New York University Langone Health, found that in cognitively normal COVID-19 patients that experienced the neurological symptom of confusion due to t…
 
Firearms are the most common method of suicide in the US over the past decade. Primary care and mental health clinicians frequently interact with individuals at risk for suicide, but clinicians are often unaware of whether these patients have access to firearms. Julie Richards, PhD, from the Kaiser Permanente Washington Health Research Institute ta…
 
In this episode, Sarah talked about attending the Alzheimer’s Association International Conference (AAIC) 2021 virtually this year and discussed increasing diversity in Alzheimer’s clinical trials as an important topic that was part of the conference. Black and Hispanic people are more likely to be diagnosed with Alzheimer’s compared to Caucasians.…
 
In this episode of TrialCard TALK, Landy and Eric welcome Mark Boesen, J.D., Pharm.D. from TC Script, TrialCard's non-commercial dispensing pharmacy located in Scottsdale, AZ. Mark discusses how TC Script has continued TrialCard's longstanding promise to always take care of patients.By TrialCard
 
In this episode, Ayesha discusses a set of recommendations for use of the new FDA-approved Alzheimer’s treatment Aduhelm (aducanumab) published by an expert panel, which was shared at the Alzheimer’s Association International Conference (AAIC) 2021 this week. Ayesha and the team talked about the controversial approval of the drug, with lingering qu…
 
In this episode, Ayesha talks about the misleading headlines that ensued after WHO chief scientist Dr. Soumya Swaminathan made comments in a press briefing about mixing and matching COVID-19 vaccines and how there is currently no data to support additional doses and boosters at this time. News agencies like Reuters were at the helm of the misleadin…
 
In this episode, Ayesha talks about Nestlé’s marketing of Seres Therapeutics’ oral microbiome drug for recurrent C. Difficile infection (CDI). CDIs are the leading cause of hospital-acquired infections in the US, with recurrence being a common problem. It typically develops after the use of antibiotics which can wipe out the gut’s healthy bacteria.…
 
In this episode, Ayesha talks about the launch of a digital marketing campaign for the first FDA-approved therapeutic video game to help treat ADHD. The video game, called EndeavorRx, is installed as an app on smart phones and tablets. It was developed by digital medicine company Akili Interactive. The game is available by prescription and is indic…
 
The COVID-19 pandemic has had far-reaching effects on the use of health care services. Dr Nora Becker of the University of Michigan talks about her research on reductions in the use of women’s preventive health services, and JAMA Health Forum Editors Dr John Ayanian and Dr Melinda Buntin discuss other JAMA Health Forum pieces on the effects of stat…
 
In this podcast, Jason Zemcik, Sr. Director of Product Management at TrialCard, breaks down the implications of this rule, outlines strategies for manufacturers to address it, and provides insight on other drug pricing policy matters that could affect how manufacturers deliver patient support programs going forward. .…
 
Hello friends, today we are going to discuss about CAPTURING METHANE LEAKS OFFERS ENVIRONMENTAL & ECONOMIC BENEFITS by Diamond Scientific company, USA.An orbiting satellite recently detected a large plume of methane in the skies above South African coal mines, highlighting the potential environmental risks associated with dirty fossil fuels. Since …
 
In this episode, Ayesha talks about a peripheral nerve stimulation system for chronic pain developed by biotech company NeuraLace that received 510(k) FDA clearance last week. The device uses electromagnetic induction technology to directly target nerves damaged from injuries like accidents, surgery and burns among others. The goal is to stimulate …
 
The COVID-19 pandemic has significantly impacted clinical operations and accelerated decentralized clinical trial models. In this podcast, TrialCard’s SVP of Business Development, Tom Heck, discusses the importance of an efficient clinical supply management process and how TrialCard’s RxStudy Card™ achieves that. Listen to this episode to understan…
 
In this episode, Latrinda Riley joins Landy Townsend, Vice President of Marketing at TrialCard, to discuss her new role as the Director of Diversity, Equity, and Inclusion. Listen to learn more about Latrinda’s background, how she managed challenges brought on by the COVID-19 pandemic, and the new initiatives she has planned for the organization.…
 
Social Media Trends 2021 and Hubspot Social Media Tools: Crystal King During the pandemic, with everybody at home, social media growth has boomed. So where does that leave social media for business? How do we best deliver, to serve this new social media awakening? In this HUG we will discover from Crystal King, a HubSpot Academy Social Media Profes…
 
In this episode, Ayesha discusses the results of a recent study that show Amazon’s Halo app can accurately estimate body fat percentage with results comparable to traditional DXA testing. The app has built-in AI algorithms that analyze images taken from a user’s smartphone, which are used to build a 3D model of the body and generate an estimate of …
 
In this episode of TrialCard TALK, our guest is Rick Ford, Vice President of Data Marketing for Policy Reporter, a TrialCard company. Rick discusses how Policy Reporter accelerates TrialCard’s mission to create the leading end-to-end patient access solutions organization by granting its clients increased visibility into health plan policy informati…
 
In this episode, Ayesha talks about a new digital fabric fiber developed by MIT researchers. The fiber contains temperature sensors and memory devices that can sense, record, analyze and store digital health data. The polymeric fiber was designed with hundreds of microscale digital chips embedded into it and can be sewn into fabrics using a needle.…
 
BioPharma EH&S Podcast Episode No. 28. Hello everybody and welcome back to another Episode of the BioPharma EH&S Podcast, my name is Dean Calhoun of Affygility Solutions and this is the podcast dedicated to discussing critical environmental, health and safety issues facing the biopharma industry, helping you take your environmental, health and safe…
 
In this episode, Ayesha talks about new research from Australia showing that eating fruit could lower the risk of developing type 2 diabetes. Researchers at the Edith Cowan University’s (ECU) Institute for Nutrition Research in Perth, Australia found that consuming at least two servings of fruit a day was linked to an over one third lower odds of d…
 
Participating in value-based incentive programs imposes financial and time costs on physician practices. Dhruv Khullar of Weill Cornell Medical College and Jason Hockenberry of Yale School of Public Health discuss these burdens, the challenge of quality measurement, and ways increase the “value” of value-based payment programs like Medicare’s Merit…
 
In this episode, Ayesha talks about Google’s new AI-based dermatology tool designed to help people identify and research conditions of the skin, hair and nails. The tool involves downloading an app on your phone and using its camera to take images of the affected area(s). These images, along with information about things like symptoms and skin type…
 
In this episode, Ayesha talks about Clinical Trials Day 2021 and how the COVID-19 pandemic spurred changes in trial procedures and perceptions of clinical research. At the onset of the pandemic, many clinical trial sites had to be shut down, prompting trial sponsors and practitioners to move to remote, decentralized clinical trial models. Researche…
 
In this episode, Ayesha discusses the latest trends in pharma tv ad spending, including the top spenders last week. The pandemic has led to a rise in both TV watching and health awareness, which pharma companies took advantage of by increasing spending on TV commercials by about 17 percent overall. Last week, three of the top ten TV ads by expendit…
 
In this episode, Ayesha discusses a new tool that uses CRISPR to modulate gene expression without editing DNA sequences. Dubbed “CRISPRoff,” the technology targets the epigenome to silence genes involved in diseases, with applications in cancer, AML and other conditions with a heritable component. The team debates the ethical considerations around …
 
Loading …

Quick Reference Guide

Copyright 2021 | Sitemap | Privacy Policy | Terms of Service
Google login Twitter login Classic login